Want To Invest In SpaceX? An IPO Looks Inevitable, But In The Meantime, Go Private Equity
If SpaceX were to go public next week it would command a valuation of somewhere in the region of $175 billion.
Walgreens Boots Alliance Cuts Higher End Of 2024 Profit Outlook, Takes $5.8B Impairment Charge Related To VillageMD Business
Walgreens Boots Alliance's Q2 FY24 performance: Sales rise 6.3% to $37.1 billion, beating estimates. Adjusted EPS up 3.4% at $1.20. Notable growth in Pharmacy segment, despite retail challenges. Revised FY24 EPS guidance: $3.20-$3.35.
Golden Cross Pattern Emerges In US Energy Stocks: Goldman Sachs Names 5 ‘Top Upstream Oil Picks’
US energy stocks form 'golden cross,' signaling potential uptrend continuation, with Goldman Sachs bullish on oil prices and top picks.
Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst
Johnson & Johnson reportedly in talks to acquire Shockwave Medical. Potential acquisition aligns with J&J's interest in expanding into cardiovascular devices. Piper Sandler considers J&J a potential buyer due to its strong financials.
Largest Animal Health Firm Zoetis Hit With European Probe Over Possible Breach of Competition Rules Related To Dog Pain Medicine
The European Commission launches probe into Zoetis over alleged market interference in dog pain medication launch. Focus on Zoetis' Librela monoclonal antibody for osteoarthritis pain relief in dogs raises antitrust concerns.
Walgreens Challenges Nearly $1B Arbitration Award Over Alleged Breach of COVID-19 Test Business Contract
Walgreens Boots Alliance challenges a nearly $1 billion arbitration award issued to telemedicine provider PWNHealth, alleging excessive damages under contract terms. The dispute revolves around Walgreens' handling of COVID-19 tests, with Everly Health Solutions asserting breach of agreement.
Medtronic’s Latest Generation Of Transcatheter Aortic Valve Replacement Implant Passes FDA’s Muster, Shares Gain
FDA approves Medtronic's Evolut FX+ TAVR system for severe aortic stenosis. Enhanced coronary access, maneuverability for diverse anatomies. Early Commercial Experience in spring 2024.
Small Caps Rally, Magnificent 7 Ease, Gold Eyes $2,200, Bitcoin Falls Below $69,000: What’s Driving Markets Wednesday?
Wall Street witnessed a mixed session on Wednesday morning trading, with tech giants seeing slight declines while blue chips and small caps recording gains.
What’s Going On European Pharma Giant AstraZeneca Stock On Wednesday?
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca challenges Arkansas law extending drug discounts to for-profit pharmacy chains, citing federal regulations."
The Most Important Catalyst For Merck’s Stock In 2024 Could Be Sotatercept Launch, Analyst Says
Cantor Fitzgerald notes Merck's robust stock performance, up 15% YTD vs S&P 500's 10%.Potential peak sales projections ranging from $1 billion to $8 billion. Merck targets 40,000 potential patients.